Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAlliance Health NC outpatient pharmacy Policy Upda…
    Ask Trek AI about this page
    Modifiedalliance_health_ncPolicy 9

    NC Medicaid Outpatient Pharmacy

    Customize your policy alerts

    Sign up for alliance_health_nc Policy 9 alerts

    Get alerted when Policy 9 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, prior authorization, dispensing limits, and pharmacy program rules for NC Medicaid outpatient pharmacy services and beneficiaries (including PHP enrollees). Applies to providers and pharmacists dispensing outpatient medications to NC Medicaid members.

    Policy Summary
    Payeralliance_health_nc
    PolicyNC Medicaid Outpatient Pharmacy
    Policy CodePolicy 9
    Change TypeMaterial amendments to coverage, lock-in thresholds, 340B billing, and new-to-market drug interim procedure
    Effective DateJul 15, 2024
    Last ReviewJul 15, 2024
    Next Review Date
    Key ActionSubmit prior authorization requests via NCTracks (web/phone/fax) with required medical records and supporting literature for off‑label/medically necessary drug requests.
    SourceLink
    POLICY UPDATE CHANGES

    Added interim procedure for new to market drugs for fee for service and managed care plans.

    Clarified that drugs must be used for FDA indications unless approval is given by DHB; provided process and required documentation to request medically necessary off-label uses supported by compendia or peer-reviewed literature.

    Changed lock-in program thresholds from 6+ claims to 10+ claims and from 3+ prescribers to 4+ prescribers and included utilization judged not medically necessary per Session Law 2023-134 HB 259.

    Added 340B guidelines clarifying billing, use of UD modifier, and entities covered; required submission of actual purchased drug price in the usual and customary charge field.

    Added section on Drug Donation and Long Acting Injectable Antipsychotics; updated record retention to electronic sources.

    15+document sections/pages listed in TOC

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10+
    lock-in threshold (changed)
    24hPA response time
    72hemergency supply allowed
    34-daydefault max supply

    Coverage, Medical Necessity, and Limits

    Coverage sections (TOC)

    Document lists sections for when services are covered, not covered, and requirements/limitations (including EPSDT exception for under 21).

    Document structure: Contains General Criteria Covered; Specific Criteria Covered; Medicaid Additional Criteria; Exceptions to FDA and NC Medicaid Drug criteria; Coverage of Compounded Drugs; Optional Drug Donation; When Not Covered; Requirements and Limitations (including Prior Authorization, Dispensing and Maximum Supply, Lock-In Program, DUR, Attachments A–K).

    Table of contents outlines the coverage sections and related attachments.

    General medical necessity criteria

    Medicaid shall cover the procedure, product, or service when medically necessary and when ALL of the following are met:

    General Criteria: 1. The procedure, product, or service is individualized, specific, and consistent with symptoms or confirmed diagnosis and not in excess of the beneficiary's needs; 2. It can be safely furnished and no equally effective, more conservative or less costly treatment is available statewide; 3. It is furnished in a manner not primarily intended for the convenience of the beneficiary, the beneficiary's caretaker, or the provider.

    Section 3.1

    General and specific drug coverage criteria

    Covered when ALL of the following are met

    General coverage criteria: 1) Individualized, specific, consistent with symptoms or confirmed diagnosis and not in excess of beneficiary's needs; 2) Can be safely furnished and no equally effective, more conservative or less costly treatment is available statewide; 3) Furnished not primarily for convenience of beneficiary, caretaker, or provider.

    Applies to drug-specific coverage determinations (Section 3.2).

    Compounded drug coverage

    Compounded products are covered when ALL of the following are true

    Compounded drug coverage: 1) A mixture of two or more ingredients is physically inseparable; 2) At least one component is a legend drug; 3) Quantity of legend drug is sufficient to have a therapeutic effect; 4) The legend drug is manufactured by a company that has signed the national Medicaid Drug Rebate Agreement with CMS.

    Refer to Attachment A Section J for billing and reimbursement details.

    Specific criteria covered by Medicaid

    Specific drug coverage conditions

    Drug-specific prerequisites: a) Drug must have FDA-approved indication or be for a medically accepted indication unless DHB approval is given; b) Drug must bear federal legend; c) Drug must be manufactured by company that signed National Medicaid Drug Rebate Agreement; d) Selected OTCs (including insulin) covered when meeting policy 9A criteria; e) Prescription must be written for the person billed; f) Vaccines covered when pharmacy complies with NC Medicaid and federal/state laws; g) Prenatal vitamins and fluoride; h) Legend calcitriol for specified beneficiaries.

    Section 3.2.1

    Non-FDA indications and approval process

    Exceptions and process for non-FDA or non-standard uses

    Off-label/compendia-supported use request: When indication or dosing falls outside FDA approved guidelines or NC Medicaid Drug Criteria, provider may request approval by submitting: medical record information showing medical necessity; explanation of other drugs tried or why they cannot be tried; prescriber's rationale why FDA/NC Medicaid guidance is insufficient; and supporting compendia or peer-reviewed literature. Send to Pharmacy Manager for Clinical Policy and Programs (address provided in policy).

    Applies per 1927(d)(1)(B)(i) and 42 U.S.C. 1396r-8(g)(1)(B).

    Abandoned LAI donation criteria

    LAI donation and abandonment rules (must ALL be met)

    LAI donation conditions: a) LAI was ordered and intended for the Medicaid beneficiary; b) Pharmacy released LAI to provider and Medicaid paid pharmacy; c) Beneficiary did not appear for administration or declined in writing; d) Provider made at least two phone calls and sent a notification letter; e) No response after three outreach attempts or beneficiary documented refusal; f) Consent to donate obtained and retained; g) Donated LAI must be in original unopened container to a registered Drug Repository Program; provider must not re-use or administer the LAI outside a registered program and must not bill Medicaid for administration if donated.30 days after missed administration (with outreach) or three outreach attempts

    Sections 3.5.1 and 3.5.1 continued

    Dispensing and substitution criteria

    Covered when pharmacy follows supply limits and substitution rules:

    Supply limits

    • Exceptions to 34-day limit: Oral birth control: up to 12 months; Prepackaged HRT: up to 3 months; Non-controlled maintenance medications: up to 90 days at provider discretion (one copay and one dispensing fee for 90-day).12 months / 3 months / 90 days

      Sections 5.4.1–5.4.2

    Generic substitution: Pharmacists must substitute generic equivalent when available unless prescriber handwrites 'medically necessary' on the prescription or other statutory exceptions apply; NC Medicaid may impose PA requirements for brand when 'medically necessary' is written.

    Section 5.8.1

    NTI substitution rules: New NTI prescriptions written by brand must be filled with generic when available unless prescriber writes 'medically necessary'; refills must use same manufacturer's product unless prescriber and beneficiary provide documented consent; use DAW 7 to indicate brand required for NTI.

    Beneficiary Management Lock-In inclusion criteria

    A beneficiary shall be locked-in to one prescriber and one pharmacy for controlled substances (opiates or benzodiazepines) when ANY of the listed thresholds are met.

    Lock-in triggers: a) Benzodiazepines: ten (10) or more claims in two (2) consecutive months when not medically necessary; b) Opiates: ten (10) or more claims in two (2) consecutive months when not medically necessary; c) Receiving prescriptions for opiates from four (4) or more prescribers in two (2) consecutive months when not medically necessary; d) Receiving prescriptions for benzodiazepines from four (4) or more prescribers in two (2) consecutive months when not medically necessary.see text

    Section 5.14.1

    Emergency supply for locked-in beneficiaries

    Emergency provision for beneficiaries locked into a different prescriber or pharmacy:

    Emergency supply rules: NC Medicaid reimburses an enrolled pharmacy for a four (4)-day supply dispensed to a beneficiary locked into a different pharmacy or prescriber in an emergent situation; provider is paid drug cost and dispensing fee; beneficiary responsible for applicable copayment; one emergency occurrence reimbursed per beneficiary each year during the two-year lock-in period; quantities paid over four days are subject to recoupment.4 days; once per year

    Section 5.14.3

    Off-label Authorization and 340B Billing

    Covered when provider demonstrates medical necessity per documentation requirements and billing rules are followed for 340B drugs.

    Off-label/Medically Necessary Approval: Provider must submit medical record evidence of necessity, include explanation of other drugs tried or why they cannot be tried, prescriber's rationale why FDA-approved guidance or NC Medicaid Drug Criteria is insufficient, and compendia or peer-reviewed literature supporting the requested use; submit to Pharmacy Manager for Clinical Policy and Programs.

    Section 3.2.3 and Revision Information; applies when indication/dosing falls outside FDA/NC Medicaid criteria.

    340B Billing Requirements: Provider must be listed on HRSA OPA website; submit actual purchased drug price in the usual and customary charge field; append 'UD' modifier to the drug detail on outpatient POS claims to indicate 340B purchase; providers maintaining two inventories may not bill Medicaid calculated price for non-340B beneficiaries; hemophilia 340B drugs may submit state upper limit where applicable.

    Revision additions and Attachment guidance (chunks 209,217).

    Compound Drug Reimbursement

    Medicaid will reimburse compounds only under the specified conditions.

    Compound reimbursement conditions: Reimbursable compounds must be a mixture of two or more physically inseparable ingredients with at least one legend ingredient; only legend drugs from manufacturers who signed the national Medicaid Drug Rebate Agreement will be reimbursed; if one ingredient lacks rebate status, reimbursement is withheld for that ingredient and the remainder may be paid; OTC ingredients reimbursed only if manufacturer signed the rebate agreement and compound contains at least one covered legend drug.

    NCPDP D.0 POS instructions and Section 3.3; see Attachment A Section J for billing details.

    Hospice Drugs

    Coverage interaction for hospice-enrolled beneficiaries:

    Hospice billing: All drug claims for hospice-enrolled beneficiaries are denied via POS as covered under hospice. An override is available by entering '1' in the PA field and the ICD-10-CM code for the beneficiary's terminal illness in the diagnosis field to allow coverage for drugs related to the terminal illness. Some drug classes (e.g., narcotic analgesics, hematinics, antiemetics, most chemotherapeutics, aromatase inhibitors) do not allow overrides and will continue to deny.

    Section H: Billing for Drugs Covered under Hospice.

    Third-Party Billing / Other Coverage

    When POS indicates third-party coverage exists:

    Primary billing required: The other third-party payer must be billed as primary before Medicaid; if beneficiary cannot produce other insurance, use Other Coverage Code '01' in claim segment 308-C8 and Medicaid will pay and pursue the third party. When other coverage exists, POS will deny the claim and require submission to the primary payer; report other coverage payment in field 431-DV when billing Medicaid secondary.

    Attachment A POS/Other Coverage instructions; override codes 01–04 described.

    Operational coverage criteria

    Coverage and dispensing allowed under the following operational conditions:

    Prior Authorization Response Time: All prior authorization requests will be answered within 24 hours of receipt when submitted via NCTracks web portal, phone, or fax; prescribers/pharmacists should follow Attachment C instructions and hours of operation.24 hours

    Attachment C (Chunks 256–257).

    Emergency supply without PA: If PA is not approved or pending, a 72-hour (3-day) emergency supply may be dispensed (use Level of Service field value '3' (418-DI) for emergency fill), with co-payments applicable; PA emergency fills are limited to 72 hours and Edit 383 prevents days supply override for PA emergency fills.72-hour

    Attachment C emergency supply rules (Chunks 256–257).

    Prospective DUR resolution: Pharmacist must resolve DUR alerts by contacting prescriber or beneficiary or using professional judgment; if dispensing, resubmit claim with NCPDP DUR reason/professional service/result of service codes. Up to three DUR alerts returned; overflow requires provider services call. Early refill edits apply (75% general, 85% for narcotics/benzodiazepines) and 34-day maximum (or 90 days where applicable).

    The table of contents for this policy includes sections titled When the Procedure, Product, or Service Is Not Covered and General Criteria Not Covered, indicating that exclusions and non‑coverage rules are explicitly defined elsewhere in the policy and are part of the coverage criteria TOC.

    Under EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) the state must cover medically necessary services for beneficiaries under age 21 to correct or ameliorate a condition. EPSDT does not, however, obligate the State to provide services that are unsafe, ineffective, experimental or investigational, or that are not medical in nature or not generally recognized as accepted medical practice.

    Medicaid excludes coverage for most OTC products unless a specific exception applies (see Subsection 3.2.1). In addition, drugs manufactured by companies that have not signed the Medicaid Drug Rebate Agreement are not covered, with limited exceptions (for example, CroFab and selected vaccines/radiopharmaceuticals). The policy also includes detailed 340B guidance describing billing and pricing obligations for covered entities.

    Automatic refills and automatic shipments are prohibited. Medicaid will not pay for any prescription (original or refill) dispensed without an explicit request from the beneficiary or the beneficiary's responsible party; prescriptions filled solely under an automatic refill policy are subject to recovery and audit.

    The policy lists specific exclusions from the Beneficiary Management Lock‑In Program. Examples include beneficiaries with certain cancer diagnoses within the prior 12 months, residents of skilled nursing facilities, beneficiaries under age 18, those with a current hospice indicator, beneficiaries receiving buprenorphine specifically for OUD, and beneficiaries with sickle cell disease.

    When 340B drugs are dispensed, providers must be listed on the HRSA 340B OPA website and must submit the actual purchased drug price in the usual and customary charge field. Providers who maintain separate inventories for 340B and non‑340B beneficiaries may not dispense a 340B‑purchased drug and bill Medicaid the calculated Medicaid price for non‑340B beneficiaries.

    The policy clarifies that providers maintaining two separate inventories — one 340B inventory and one purchased inventory for non‑340B beneficiaries — are prohibited from using 340B‑purchased product to bill Medicaid at the calculated Medicaid price for non‑340B beneficiaries; separate inventory management does not permit cross‑billing.

    Examples of non‑reimbursable compound scenarios are provided. Compounds are non‑reimbursable when they contain no legend‑covered drug, when all ingredients are from non‑rebate manufacturers, when only OTC or DESI ingredients are used, when the compound is equivalent to an OTC product, or when two physically separable products (e.g., tablets and capsules) are combined in the same container.

    Early refill reason codes for vacation supply and lost prescription are not permitted for controlled substances. The policy specifies that vacation‑supply and lost‑prescription codes cannot be used to authorize early refills of controlled drugs.

    The table of contents includes a section labeled Specific Criteria Not Covered (TOC), indicating that particular exclusions and noncoverage rules are defined elsewhere in the full policy document.

    Services, products, or procedures are not covered when the beneficiary fails to meet eligibility requirements in Section 2.0, when they do not meet the criteria in Section 3.0, when the service duplicates another provider's service, or when the service is experimental, investigational, or part of a clinical trial.

    A prescriber's telephone or e‑prescription notation, a stamped or pre‑printed 'Medically Necessary' statement, or the simple abbreviation 'DAW' on a prescription are not acceptable documentation to establish medical necessity for MAC overrides; the policy requires proper handwritten, signed notation or follow‑up prescription as described for MAC exceptions.

    Medicaid will not pay for medications the beneficiary has not received. Pharmacies may not bill for undispensed quantities, issue IOUs, or bill Medicaid for an entire prescription if part of the quantity was not dispensed; doing so may be considered fraudulent and is subject to action.

    Utilization that is determined to be not medically necessary can trigger programmatic actions — including inclusion in the Beneficiary Management Lock‑In Program — and may affect coverage and reimbursement decisions.

    Claim Fields, Codes, and POS Rules

    Attachment references (no codes present)mixed
    No codes listed
    Referenced reimbursement/code listsmixed
    SMACState Maximum Allowable Cost list (as referenced in B.4)
    NDCNational Drug Code (as referenced in B.6)
    NDC manufacturer code guidanceNDC
    NDC (first five digits)Manufacturer code indicated by the first five digits of the 11-digit NDC determines rebate applicability
    DAW override codesModifier
    DAW 1NADAC generic rate and MAC override for prescriber's handwritten 'Medically Necessary'
    DAW 7NADAC generic rate and MAC override for NTI brand required
    DAW 8NADAC generic rate and MAC override when multi-source brand generic equivalent not available
    DAW 9NADAC generic and MAC override for preferred multi-source brand with nonpreferred generic
    DAW usageModifier
    DAW 1Indicate prescriber-documented 'Medically Necessary' to bill brand when overriding MAC price (use to bill brand when prescriber properly authorizes brand for a MAC drug).
    NDCs and required metric decimal quantities when billingNDCCovered
    00075150616Nasacort AQ Nasal Spray — metric decimal quantity 16.5
    00597001314Combivent Inhaler — metric decimal quantity 14.7
    00186107008Rhinocort AQUA Nasal Spray — metric decimal quantity 8.6
    00075062160Lovenox 60mg prefilled syringe — metric decimal quantity 0.60
    00013830304Xalatan 0.005% Eye Drops — metric decimal quantity 2.5
    00069313019Zithromax 200mg/5ml Suspension — metric decimal quantity 22.5
    00065064835Tobradex Eye Ointment — metric decimal quantity 3.5
    00054309036Butorphanol 10mg/ml Spray — metric decimal quantity 2.5
    00085113201Proventil HFA 90 mcg Inhaler — metric decimal quantity 6.7
    61570003775Viroptic 1% Eye Drops — metric decimal quantity 7.5
    Emergency override codemixed
    09Emergency Preparedness PA Type Code
    Emergency override E.R. override values (claims fields)mixed
    E.R overrideValid value required in Reason for Service/Professional Service/Result of Service to override early refill during emergency
    340B modifierModifier
    UDModifier to indicate 340B purchase on drug detail for outpatient pharmacy point-of-sale claims (and UB-04/837i for institutional outpatient medical drug claims)
    Vaccine billing codesCPT
    CPT (vaccines)Use appropriate CPT codes and pharmacy NPI/taxonomy when billing vaccines as professional claims
    POS/Other Payer Fields and Override Codesmixed
    308-C8Other Coverage Code (NCPDP D.0) - override codes for cost avoidance process
    431-DVOther Coverage Amount Paid field
    353-NRMedicare Coinsurance field (used for QMB claims)
    351-NPMedicare Deductible field (used for QMB claims)
    352-NQMedicare Copayment field (used for QMB claims)
    POS claim segments/fieldsNCPDP
    308-C8Other Coverage Code (claim segment)
    431-DVOther Coverage Amount (field for secondary payor amount)
    Other Coverage Override CodesNCPDP
    01No Other Coverage Identified
    02Other Coverage Exists - Payment Collected
    03Other Coverage Exists - This Claim Not Covered
    04Other Coverage Exists - Payment Not Collected
    Compound drug EOB codesEOB
    EOB 1Requirement not met (compound without a legend-covered drug / non-rebate drugs / OTC only etc.)
    905,1A compound without a legend-covered drug or a compound with only non-rebate drugs
    038,1OTC and DESI drugs as only ingredients
    009,1A compound equivalent to an OTC drug; OTC ingredients only; two physically separable drugs in same bottle
    POS transaction fieldsNCPDP
    418-DILevel of Service field used to indicate emergency fill (value '3' for emergency supply)
    DUR early refill reason codesNCPDP
    03Vacation Supply reason code for early refill
    04Lost Prescription reason code for early refill
    05Therapy Change reason code for early refill
    inv-45: Point-of-sale claim value threshold
    POS claim value threshold> $9,999 — claims submitted at point-of-sale over this amount require manual review for validity
    ContextPOS handling described in Attachment A: Point-of-Sale Claims over $9,999 (manual review required)
    Action for providersCheck remittance advice or NCTracks for manual review results before assuming payment

    Prior Authorization, Documentation, and Operational Steps

    Prior Authorization

    Prior Authorization Required; LTC pharmacists may request PA

    Prior authorization is required for selected outpatient prescription drugs; providers must follow the PA process described in Attachment C and the Pharmacy Prior Approval Criteria in Attachment K. Pharmacists serving long‑term care facilities may request prior authorization on behalf of beneficiaries per the special LTC PA process.

    Prior Authorization

    How to Submit Prior Authorization Requests

    Submit PA requests using the NCTracks web portal, by phone, or fax as described in Attachment C; all PA requests will be answered within 24 hours of receipt.

    Prior Authorization

    PA Required for Selected and New‑to‑Market Drugs

    Selected prescription drugs require prior authorization per NCTracks and Attachment K; PA may be imposed for new‑to‑market products, changed indications, or changes in dosing while criteria are developed.

    Policy Scope and Attachments

    This policy's background and attachments focus on administrative and claims processing details. Attachment A–E are included and provide directions for drug reimbursement, the SMAC list, billing guidance for vaccines and compounds, point‑of‑sale rules, and other claims‑related instructions relevant to outpatient pharmacy coverage and payment.

    Key Terms and Abbreviations

    inv-129: Long Acting Injectable (LAI) listed as defined term in TOC.
    Defined term: Long Acting Injectable (LAI)Long Acting Injectable (LAI) — injectable formulations intended for prolonged or sustained drug release over a period ranging from a few days to months (listed in TOC/definitions)
    LocationListed in Table of Contents under Definitions (1.1)
    Cross-referenceSee Optional Drug Donation and Abandoned LAI sections for handling rules
    inv-130: Narrow Therapeutic Index (NTI) listed as defined term in TOC.
    Defined term: Narrow Therapeutic Index (NTI)Narrow Therapeutic Index (NTI) — pharmaceuticals having a narrowly defined range between risk and benefit (listed in TOC and described under NTI section)
    CharacteristicsMay have less than twofold difference between toxic and effective blood concentrations; may require blood-level monitoring

    Utilization Management and Step Therapy

    StepRequirement / PolicyNotes
    1NCPAG may recommend prior authorization criteria and other restrictions for drugs designated as episodic; quantity limitations may be applied.Recommendations may include evaluation of quantity limits for beneficiaries using specialized distribution systems, development of prior authorization criteria, and actions to minimize number of dispensing fees.
    StepInterim ProcedureProvider Requirements
    1An interim procedure was added for new-to-market drugs applying to fee-for-service and managed care plans.Providers requesting coverage for new-to-market or non-standard indications must submit medical records showing medical necessity, explanation of alternatives tried or why they cannot be tried, prescriber's rationale why FDA/NC Medicaid criteria are insufficient, and supporting compendia or peer‑reviewed literature.

    Dispensing Limits and Quantity Rules

    inv-149: Birth control and hormone replacement therapies — see Dispensing and Maximum Supply section.
    Birth control and HRT supply guidanceSee Dispensing and Maximum Supply section: oral birth control up to 12 months; prepackaged HRT up to 3 months
    General supply defaultsDefault maximum supply for outpatient drugs is 34 days; exceptions include 90-day non-controlled maintenance and contraceptives/HRT as noted
    Related sectionRefer to Section 5.4 Dispensing and Maximum Supply for details
    inv-150: All outpatient drugs supply defaults and exceptions.
    All outpatient drugs supply defaults and exceptionsDefault 34-day supply; non-controlled maintenance medications may be dispensed up to 90 days; oral contraceptives up to 12 months; prepackaged HRT up to 3 months
    Copay/fee for 90-day supply

    Authorized Settings and Site-Specific Rules

    Note
    Note
    Note
    Note
    Policy Summary
    Payeralliance_health_nc
    PolicyNC Medicaid Outpatient Pharmacy
    Policy CodePolicy 9
    Change TypeMaterial amendments to coverage, lock-in thresholds, 340B billing, and new-to-market drug interim procedure
    Effective DateJul 15, 2024
    Last ReviewJul 15, 2024
    Next Review Date
    Key ActionSubmit prior authorization requests via NCTracks (web/phone/fax) with required medical records and supporting literature for off‑label/medically necessary drug requests.
    SourceLink
    On This Page
    Coverage, Medical Necessity, and LimitsClaim Fields, Codes, and POS RulesPrior Authorization, Documentation, and Operational StepsPolicy Scope and AttachmentsKey Terms and AbbreviationsUtilization Management and Step TherapyDispensing Limits and Quantity RulesAuthorized Settings and Site-Specific Rules

    Section 5.8.2

    MAC/NADAC overrides: Prescriber handwritten and signed 'medically necessary' may override NADAC or State MAC reimbursement; appropriate DAW code must be used; unacceptable documentation methods (telephone, e-prescription notation, stamps, pre-printed text, 'DAW' abbreviation) do not establish medical necessity for override.

    Sections 5.9 and attachments

    75% / 85% / 34-day

    Attachment D and Pro-DUR procedures (Chunks 264–268).

    inv-46: LAI abandonment timeframe
    LAI abandonment timeframe30 days after the missed administration date following at least two phone call outreach attempts and a notification letter, or after three documented outreach attempts with no response
    Documentation requiredProvider must document outreach attempts and retain signed donor consent if donating an abandoned LAI
    DispositionOnce considered abandoned, LAI must be donated in original unopened container to a registered Drug Repository Program; provider may not reuse or administer to another patient outside program
    inv-47: Supply limits
    Default maximum supply34-day supply for all drugs unless an exception applies
    Non-controlled maintenance medicationsUp to 90-day supply at prescriber's discretion (one copay and one dispensing fee for 90-day supply)
    Oral birth controlUp to 12 months supply permitted
    Prepackaged hormone replacement therapy (HRT)Up to 3 months supply permitted
    inv-48: Beneficiary lock-in claim threshold
    Lock-in claim thresholdTen (10) or more claims in two (2) consecutive months for opiates or benzodiazepines (when not medically necessary)
    Prescriber count triggerReceiving prescriptions from four (4) or more prescribers in two (2) consecutive months can also trigger lock-in
    Program effectBeneficiary locked into one prescriber and one pharmacy for controlled substances when criteria met
    inv-49: AAC pricing preference
    Preferred AAC pricing sourceUse NADAC for Average Acquisition Cost (AAC) when NADAC is available
    Fallback when NADAC unavailableUse Wholesale Acquisition Cost (WAC) and then apply the lessor of WAC; state MAC price; hemophilia enhanced specialty discount (if applicable); or UCR to determine cost
    PublicationState MAC and hemophilia discount lists are published on NC Medicaid's website; AAC available in State Plan Attachment 4.19-B
    inv-50: Manual review threshold
    Manual review thresholdClaims over $9,999 require manual review for validity
    POS handlingPOS captures the claim but payment determination is pending until manual review completes; check RA or NCTracks for status
    Provider actionMonitor remittance advice or NCTracks to confirm claim acceptance after manual review
    inv-51: POS claim submission time limit
    Time limit to submit POS claimsPoint-of-sale claims must be billed within one (1) year of the dispensing date
    ImplicationClaims submitted after one year from dispense date may be denied; maintain timely submission practices
    ReferenceSee Attachment A: Time Limit for Point-of-Sale Claims
    inv-52: POS reversal window
    POS reversal windowPoint-of-sale reversals are allowed up to twelve (12) consecutive months after the dispense date
    Override instructionUse appropriate POS fields per NCPDP D.0 instructions to submit reversals within the allowed window
    Provider actionProcess reversals promptly and ensure documentation supports reversal within 12 months
    inv-53: Early refill threshold for narcotics and benzodiazepines
    Narcotics and benzodiazepines early refill thresholdEarly refills allowed after 85% of the days supply has been used
    RationalePro-DUR edits enforce early refill thresholds to prevent premature dispensing of controlled substances
    Related DUR action codesUse appropriate DUR reason/professional service codes when overriding after DUR resolution
    inv-54: Early refill threshold for other drugs
    Early refill threshold (other drugs)Early refills for non-narcotic/non-benzodiazepine drugs allowed after 75% of the days supply has been used
    System enforcementPro-DUR uses days-supply/quantity to calculate daily dose and enforce early refill edits
    ExceptionsSome edits can be resolved with documented DUR professional service codes; follow Pro-DUR procedures
    inv-55: Maximum days supply for vacation supply
    Maximum vacation supply (default)34 days maximum days supply for vacation supply (applies generally)
    90-day exceptionVacation or early refill rules may allow 90 days if the 90-day exception for non-controlled maintenance medications applies
    Controlled substancesVacation supply and lost prescription early refill reason codes are not allowed for controlled substances
    Prior Authorization

    72‑Hour Emergency Supply While Awaiting PA

    If a beneficiary is waiting for PA acknowledgement, the pharmacy may provide a 72‑hour emergency supply; refer to Attachment C for processing details.

    • Use Level of Service field value '3' (418‑DI) for emergency fills.
    • Emergency fills permit only a 72‑hour supply and co‑payments apply.
    Prior Authorization

    PA May Be Required for Handwritten 'Medically Necessary' Brand Orders

    NC Medicaid may require PA for brand drugs when the prescriber handwrites 'medically necessary' on the prescription; DAW/MAC override rules and PA requirements apply as described in the MAC and Generic Substitution sections.

    • Handwritten, signed 'Medically Necessary' by the prescriber is required for MAC/NADAC override (DAW 1,7,8,9 as applicable).
    • NC Medicaid may impose PA for brand‑name drugs when 'medically necessary' is indicated.
    Note

    Hemophilia Specialty Pharmacy Authorization

    Hemophilia drugs are managed under the mandated Hemophilia Specialty Pharmacy Program; follow Clinical Coverage Policy 9B for program‑specific authorization rules.

    Prior Authorization

    Emergency PA Override Submission Requirements

    When the Emergency Preparedness Protocol is enacted, submit pharmacy claims with '09' in the PA Type Code field and include a valid emergency override value in the Reason for Service/Professional Service/Result of Service fields to override early‑refill denials.

    • Use PA Type Code '09' (Emergency Preparedness) on POS claims.
    • Provide a valid ER override value in DUR/Result of Service fields to override early refill denials.
    Prior Authorization

    PA for Off‑Label or Non‑criteria Indications — Documentation Required

    Prior authorization is required for selected drugs and requests for off‑label/non‑criteria indications must include the required supporting documentation described in policy (medical records, alternatives tried, prescriber rationale, and compendia/peer‑reviewed literature).

    • Send supporting materials to: Pharmacy Manager for Clinical Policy and Programs, Division of Health Benefits, NC Medicaid, 2501 Mail Service Center, Raleigh, NC 27699‑2501.
    Prior Authorization

    DME Prior Authorization for Diabetic Supplies

    Prior authorization for additional quantities or non‑preferred diabetic supplies must be requested through the DME Program rather than outpatient pharmacy POS.

    Billing Rule

    Other Coverage / Override Codes and Secondary Billing

    When billing Medicaid as secondary payer, report other coverage using the Other Coverage Code in claim segment 308‑C8 and report the other payer payment amount in field 431‑DV per Attachment A instructions.

    • Use '01' in 308‑C8 when no other coverage identified; when other payer paid, include amount in 431‑DV.
    Prior Authorization

    Prior Authorization Submission Channels and Response Time

    Submit PA requests via NCTracks web portal, phone, or fax; all requests will be answered within 24 hours. If PA is not obtained, the POS will return PA‑required messages and the pharmacy may contact CSC or the prescriber to resolve status.

    • If POS returns 'PA REQ. PRESCRIBER CALL CSC' or 'CLAIM DENIED. PA LIMITS EXCEEDED', verify PA status through NCTracks or CSC (1‑866‑246‑8505).
    Step Therapy

    Step Therapy Not Described in Excerpt

    This excerpt contains only table‑of‑contents headings for step therapy; no step therapy requirements or specific step protocols are described in the provided text.

    Documentation Required

    DUR Resolution and Documentation Requirements

    The policy references DUR and prospective/retrospective review processes; pharmacists must resolve DUR alerts by contacting prescriber or beneficiary and, when dispensing after resolution, resubmit the claim with DUR reason/professional service/result of service codes.

    • If dispensing after DUR resolution, include DUR reason for service, DUR professional service code, and DUR result of service code on resubmitted claim.
    • For early‑refill alerts use approved reason codes in the clarification field.
    Documentation Required

    Record Retention and Audit‑Readiness

    Providers must retain Medicaid records on‑site and produce sight‑readable original and refill prescription records and purchase invoices for audits; payments that cannot be audited because records are not retrievable are subject to recoupment.

    • Electronic records are acceptable if readily retrievable and sight‑readable per enrollment agreement.
    • Maintain purchase invoices for all covered drugs and supplies on‑site.
    Documentation Required

    Documentation Required for Off‑Label / Medically Necessary Requests

    When requesting coverage for non‑FDA or non‑criteria dosing/indications, submit medical record evidence of necessity, explanation of alternatives tried or why they cannot be tried, prescriber rationale why FDA/NC criteria are insufficient, and supporting compendia or peer‑reviewed literature.

    Documentation Required

    Handwritten 'Medically Necessary' and DAW/MAC Override Rules

    Pharmacies that accept a prescriber's handwritten, signed 'Medically Necessary' statement may use DAW overrides (DAW 1, 7, 8, 9) to override NADAC/MAC pricing as described; telephone, e‑prescription, stamps, or 'DAW' abbreviation on the prescription are unacceptable forms of documentation.

    • DAW 1 on POS indicates prescriber handwritten 'Medically Necessary' and is a NADAC/MAC override where appropriate.
    • Unacceptable practices (phone eprescription, stamps, boxed 'Dispense as Written' checks) will not support MAC override.
    Documentation Required

    NTI Refill and Manufacturer Consent Requirements

    NTI refill rules: subsequent refills must use the same manufacturer's product unless prescriber and beneficiary provide documented consent to switch manufacturers; use DAW 7 to indicate brand required for NTI.

    Billing Rule

    Verify Eligibility Each Time; POS Coverage Flags

    Providers must verify beneficiary eligibility each time a service is rendered; POS will check eligibility and return messages if other third‑party coverage exists or beneficiary is enrolled in hospice.

    • If POS indicates other payer exists, bill the third party as primary before billing Medicaid.
    • POS notifies pharmacist when beneficiary is enrolled in hospice; hospice claims are denied unless hospice override is used.
    Denial Risk

    NDC Accuracy and 11‑Digit Formatting Requirement

    Incorrect or improperly formatted NDCs (fail to include all 11 digits with leading zeros placed correctly) will result in claim denial; pharmacies must use the NDC actually dispensed and record all 11 digits in the proper positions.

    • Example formatting guidance provided (leading zeros required).
    • Inaccurate NDC use may lead to denials, sanctions, or termination.
    Denial Risk

    POS Claim Triggers — High‑Value and Compound Claims

    POS claim handling rules apply to high‑value and compound claims: point‑of‑sale claims over $9,999 and compound prescription claims have special processing and failure to follow these rules may trigger manual review, denials, or audits.

    • Claims over $9,999 may require manual review.
    • Compound reimbursement limited to legend drugs from manufacturers with Medicaid Drug Rebate Agreements; POS pays payable ingredients only.
    Denial Risk

    Automatic Refills Prohibited — Risk of Recovery/Audit

    Automatic refills and automatic shipments are prohibited; pharmacies must obtain an explicit beneficiary (or responsible party) request for each refill — unauthorized fills are subject to recovery, audit, or provider agreement suspension/termination.

    Denial Risk

    Hospice Billing Override Instructions and Denial Risk

    If a beneficiary is enrolled in hospice, POS will deny drug claims with 'beneficiary claim covered by hospice' unless the pharmacist enters '1' in the PA field and the ICD‑10‑CM code for the terminal illness in the diagnosis field to override for drugs related to the terminal illness; certain drug classes cannot be overridden and will continue to deny.

    • Pharmacists must not use the ICD‑10‑CM code for the drug indication; contact hospice agency or NC Medicaid for questions.
    Denial Risk

    PA Missing Triggers POS Denial Messages

    If a prescriber has not obtained required prior authorization, the POS will return messages such as 'PA REQ. PRESCRIBER CALL CSC' or 'CLAIM DENIED. PA LIMITS EXCEEDED' and the claim may be denied at point‑of‑sale; pharmacies should verify PA status via NCTracks or CSC.

    • Contact CSC at 1‑866‑246‑8505 or use the NCTracks web portal to verify or obtain PA status.
    Prior Authorization

    Emergency Supply Limits and POS Edit Restrictions

    Emergency fills bypassing PA allow only a 72‑hour supply; use Level of Service field value '3' (418‑DI) for emergency transactions and include required edits — Edit 383 prevents overriding days supply for PA emergency fills.

    • Emergency fill transactions must be submitted with Level of Service = '3' (418‑DI).
    • Edit 383 message: 'CANT USE OVERRIDE WITH A PA EMER FILL'.
    Denial Risk

    Eligibility, Duplication, and Not‑Medically‑Necessary Denial Risks

    Claims may be denied for eligibility, duplication, or services not meeting Sections 2.0/3.0 criteria; utilization judged not medically necessary can also trigger lock‑in program inclusion and affect coverage decisions.

    • Utilization considered not medically necessary may result in administrative actions including recoupment and lock‑in enrollment.
    Documentation Required

    State MAC Inquiry — Documentation and Process

    Providers requesting a State MAC rate review must complete a State MAC Pricing Inquiry Worksheet and submit copies of drug purchase records representing current price paid; the vendor may contact other pharmacies/manufacturers during review.

    Billing Rule

    Compound Claim Billing and Reimbursement Requirements

    Providers billing compounds at POS must ensure compound ingredients are reimbursable (legend drugs from manufacturers with Drug Rebate Agreements); if one ingredient lacks rebate status reimbursement is withheld for that ingredient only and the remainder may be paid.

    • POS assumes submission clarification indicating payable ingredients only when appropriate.
    • Dispensing fee must be included in header total and ingredient details must match POS compound component count.
    Billing Rule

    Claims Documentation and POS Billing Instructions

    Providers must follow Attachment A claim‑related instructions including point‑of‑sale billing, time limits (POS claims within 1 year of dispensing), compound claims rules, and required remittance/Explanation of Benefit handling.

    • Time limit for POS claim submission: within 1 year of dispensing date.
    • POS reversals are allowed up to 12 consecutive months.
    Documentation Required

    Record Retention, On‑Site Documentation, and Recoupment Risk

    If a provider cannot produce on‑site, sight‑readable Medicaid records (original prescriptions, refill history, purchase invoices), payments may be recouped; pharmacies are subject to periodic audits and must cooperate with investigations.

    Documentation Required

    Documentation and Consent Required for Abandoned LAI Donation

    For LAI donation of abandoned doses, obtain and retain a signed consent from the beneficiary donor that explains when an LAI is considered abandoned and document outreach attempts; do not bill Medicaid for administration of donated LAIs.

    • LAI considered abandoned after 30 days post‑missed administration and at least two calls plus a letter, or after three outreach attempts or documented refusal.
    • Donated LAIs must be in original unopened container and donated to a registered Drug Repository Program.
    Billing Rule

    340B Billing Documentation and UD Modifier Requirement

    When billing 340B‑purchased outpatient drugs at POS, ensure the provider is listed on the HRSA 340B OPA website, submit the actual purchased drug price in the usual & customary charge field, and append the UD modifier to indicate a 340B purchase; do not bill the 340B Medicaid price for non‑340B beneficiaries when maintaining separate inventories.

    • For hemophilia 340B drugs, providers may submit the state upper limit when applicable.
    Prior Authorization

    PDL Override When PA Criteria Met

    PDL overrides are allowed when 'Meets PA Criteria' is documented per Attachment B; ensure the PA documentation supports the PDL override.

    Documentation Required

    MAC Override Requirements and Acceptable Documentation

    MAC price overrides require proper prescriber documentation and use of DAW codes (DAW 1, 7, 8, 9) as specified; telephone or e‑prescription notations alone are unacceptable to support MAC overrides.

    • DAW 1 indicates prescriber's handwritten 'Medically Necessary' and may override MAC/NADAC where allowed.
    • DAW 7 used for NTI brand required; DAW 8/9 as described for market availability and PDL preferences.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Review cycleNTI drug list is reviewed annually and published in Attachment D
    inv-131: Drug Use Review (DUR) listed as defined term in TOC.
    Defined term: Drug Use Review (DUR)Drug Use Review (DUR) — prospective and retrospective processes to ensure prescriptions are appropriate, medically necessary, and not likely to result in adverse outcomes (defined in TOC; see Attachment E G.9)
    Prospective DUR (Pro-DUR)Screening at time a new prescription is filled to identify therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect dosage/duration, allergies, and misuse
    Response requirementPharmacist must document DUR alert resolution with appropriate NCPDP DUR result of service and professional service codes before payment on resubmission
    inv-132: State Maximum Allowable Cost (SMAC) List referenced as Attachment A (definition context limited in excerpt).
    Referenced: State Maximum Allowable Cost (SMAC) ListSMAC List referenced in Attachment A (B.4) as the state MAC pricing list used when NADAC is unavailable; definition context limited in excerpt
    PublicationState MAC lists are published on NC Medicaid's website and updated monthly
    Use caseUsed as part of AAC/WAC fallback pricing for drug ingredient cost determination
    inv-133: Hemophilia Specialty Pharmacy Program referenced (definition context limited in excerpt).
    Referenced: Hemophilia Specialty Pharmacy ProgramHemophilia Specialty Pharmacy Program is referenced in Attachment A (B.5); program-specific clinical/authorization rules appear in Clinical Coverage Policy 9B
    340B/hemophilia pricing noteHemophilia enhanced specialty discount is factored into AAC/WAC fallback pricing when applicable
    LocationAttachment A: Claims-Related Information lists Hemophilia Specialty Pharmacy Program (B.5)
    inv-134: Legend Drugs definition referenced in TOC/definitions.
    Defined term: Legend DrugsLegend Drugs — drugs defined by the Federal Food, Drug and Cosmetic Act whose label must state 'Caution: Federal law prohibits dispensing without prescription.'
    LocationListed under Definitions (1.1) in the Table of Contents
    Reimbursement relevanceCompound reimbursement requires at least one legend (covered) ingredient manufactured by a rebate-participating company
    inv-135: DUR definition reference (Attachment E:G.9).
    DUR definition referenceDrug Use Review (DUR) — see Attachment E: G.9 for detailed definition and criteria; Pro-DUR screening described in Attachment C and overview sections
    FunctionDUR program ensures prescriptions are appropriate, medically necessary and reduces adverse drug events
    DocumentationPharmacists must document actions taken to resolve DUR alerts using NCPDP codes when dispensing after resolution
    inv-136: NTI definition noted (narrow therapeutic index concept).
    NTI definition noteNTI — pharmaceuticals with narrow safety margins; less than twofold difference between toxic and effective blood concentrations or other specified pharmacokinetic concerns
    Regulatory basisNTI drugs designated by Secretary of N.C. DHHS upon advice of State Health Director, NC Board of Pharmacy, and NC Medical Board
    Operational noteRefer to Attachment D for the current NTI drug list (reviewed annually)
    inv-137: LAI definition noted (injectables for prolonged release).
    LAI definition noteLAI — injectable formulations intended for prolonged/sustained drug release over days to months (defined in 1.1); optional drug donation and abandoned LAI rules specified in Section 3.5
    Abandonment connectionAbandoned LAI handling and donation conditions reference the LAI definition and donation procedures
    Provider actionsProviders must obtain signed consent and document outreach attempts per abandoned LAI rules before donation
    inv-138: Abandoned LAI definition — LAI dispensed to provider for administration to a specific beneficiary and considered abandoned under certain conditions.
    Abandoned LAI (defined)An LAI dispensed to a provider for administration to a specific beneficiary is considered 'abandoned' if beneficiary fails to appear and outreach/timeframe conditions are met (30 days after missed administration and specified outreach attempts), allowing donation under specified documentation requirements
    Donation requirementProvider must retain signed donor consent and donate only to a registered Drug Repository Program in original unopened container
    ProhibitionsProvider must not reuse or administer the abandoned LAI to another patient outside a registered repository program
    inv-139: Refilled definition reference — New prescription written at expiration continuing therapy on NTI drug.
    Refilled (NTI context)'Refilled' means a new prescription written at the expiration of a prescription which continues the beneficiary's therapy on a narrow therapeutic index drug
    NTI refill ruleSubsequent NTI refills must use same manufacturer's product unless prescriber and beneficiary give documented consent to switch
    DAW codingUse DAW 7 to indicate brand required for NTI when applicable
    inv-140: State MAC definition — Program used to set reimbursement rates when NADAC unavailable.
    State MAC (definition)State Maximum Allowable Cost (State MAC) — program list used to set reimbursement rates for multi-source generics and certain brand products when NADAC is unavailable
    CalculationState MAC reimbursement is based on percentage factors applied to lowest-priced generics, with adjustments when necessary; updated monthly
    Role in pricing fallbackState MAC used as part of AAC/WAC fallback pricing when NADAC is not available
    inv-141: NTI drug characteristics — Less than twofold difference between toxic and effective blood concentrations or similar criteria.
    NTI drug characteristicsDrugs with less than twofold difference between minimum toxic and minimum effective blood concentrations or those with limited/erratic absorption, formulation-dependent bioavailability, or wide intrapatient variability requiring blood-level monitoring
    Designation processNTI drugs are designated by the Secretary of N.C. DHHS with input from state boards and published annually (Attachment D)
    Operational impactNTI rules affect substitution and refill requirements and DAW usage
    inv-142: Medically accepted indication defined per 1927(k)(6) — FDA-approved use or supported by compendia/peer-reviewed literature.
    Medically accepted indication (statutory)Defined per 1927(k)(6): any use FDA‑approved or supported by specified compendia (AHFS, USP, DRUGDEX) or peer‑reviewed medical literature
    Use for PA requestsRequests for off‑label/medically necessary uses must include supporting compendia or peer‑reviewed literature and medical record justification
    Regulatory referenceCites Section 1927(d)(1)(B)(i) and 1927(k)(6) of the Social Security Act for standards
    inv-143: NDC definition — 11-digit identifier for drug product and package size.
    NDC definitionNational Drug Code (NDC) — an 11‑digit identifier for drug product and package size composed of three fields (5-4-2); leading zeros required for proper placement
    Claim riskFailure to record all 11 digits in proper position will result in a claim denial
    ExampleExample formatting shown in policy (e.g., Inderal 20 mg: 00046042281)
    inv-144: PROCESS COMPOUND FOR APPROVED INGREDIENTS — POS assumes specific clarification field value for payable ingredients.
    PROCESS COMPOUND FOR APPROVED INGREDIENTS (POS behavior)POS assumes submission clarification field value '8' meaning the compound is processed for approved (payable) ingredients only
    Compound claim requirementTotal ingredients billed must match the compound ingredient component count and include cost for each ingredient and the dispensing fee
    Effect of non-covered NDCsIf compound includes NDCs not covered by Medicaid, POS processes payable ingredients only
    inv-145: Prospective DUR (Pro-DUR) definition — Screening at time new prescription is filled.
    Prospective DUR (Pro-DUR) definitionScreening performed at time a new prescription is filled to identify potential drug therapy problems (therapeutic duplication, contraindications, interactions, incorrect dosage/duration, allergies, misuse)
    RequirementPharmacies participating in Medicaid must conduct Pro‑DUR screening using software or written standards consistent with the DUR Board policy
    DocumentationDUR conflicts must be documented with NCPDP DUR result of service and professional service codes for payment on resubmission
    inv-146: NTI drugs list reference — NTI drugs reviewed annually and listed (examples provided in full policy).
    NTI drugs list referenceNTI drugs list is reviewed annually and published (Attachment D) — examples include carbamazepine, digoxin, warfarin, lithium, tacrolimus, levothyroxine, etc.
    AccessRefer to Attachment D: Narrow Therapeutic Index Drugs for full current list
    Operational noteNTI designation affects substitution and refill rules described in policy
    Only one copay is collected and only one dispensing fee is paid for the 90-day supply
    Prescriber discretion90-day supply for non-controlled maintenance is at the prescriber's discretion
    inv-151: Locked-in controlled substances dispensed to different pharmacy/prescriber — emergency allowance (4 days).
    Locked-in beneficiary emergency allowanceWhen a locked-in beneficiary obtains a controlled substance from a different pharmacy/prescriber in an emergency, NC Medicaid reimburses a 4-day supply once per year during the two-year lock-in period
    Payment detailsProvider paid drug cost and dispensing fee; beneficiary responsible for applicable copayment
    Recoupment riskPaid quantities exceeding a 4-day supply are subject to recoupment
    inv-152: Test strips — billing increments in multiples of 50 or 51.
    Test strips billing incrementTest strips must be billed in multiples of 50 or 51 at point-of-sale
    Syringes and lancets billing incrementSyringes and lancets must be billed in multiples of 100
    Lancing device quantityOne (1) lancing device equals one unit for Medicaid billing
    inv-153: Syringes and lancets — billing increments in multiples of 100.
    Syringes and lancets billing incrementSyringes and lancets must be billed in multiples of 100
    RationaleRequired by POS claims processing for diabetic supplies; rates align with DME program
    PA for additional quantitiesPrior authorization for additional quantities or non-preferred diabetic supplies must be processed through the DME Program
    inv-154: Lancing device — quantity allowed = 1.
    Lancing device quantity allowedQuantity allowed = 1 (one lancing device equals one unit)
    Billing noteRates apply to these diabetic supplies; therefore, no copayments and no dispensing fees apply for these items when billed under Medicaid DME rules
    Related guidancePrior authorization for additional quantities must go through DME Program